Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Processed 3,664 EsoGuard ® tests and recognized 4Q25 revenue of $1.5 million Expanded EsoGuard access with U.S. Department of Veterans Affairs contract award and strengthened clinical evidence with positive data from the largest reported real-world experience of esophageal precancer detection Conference call and webcast to be held today, March 26, at 8:30 AM EST NEW YORK, March 26, 2026 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM) ("PAVmed"), today provided a business update for the Company and reported financial results for the fourth quarter and full year ended December 31, 2025. Conference Call and Webcast The webcast will take place on Thursday, March 26, 2026, at 8:30 AM and will be accessible in the investor relations section of the Company's website at luciddx.com.